Athira Pharma (ATHA) announced the appointment of Javier San Martin, M.D., as Chief Medical Officer. Dr. San Martin brings more than 25 years of drug development experience and a proven track record leading cross-functional product teams to drive global development and commercialization strategies for multiple drugs across large and rare diseases with significant unmet medical need. San Martin joins Athira from Arrowhead Pharmaceuticals (ARWR), where he served as Chief Medical Officer and guided development teams to advance that company’s RNAi-based therapeutics in the metabolic and liver disease area
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ATHA:
- Athira Pharma announces publication of preclinical data on fosgonimeton
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
- Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
- Athira Pharma presents clinical, preclinical data of fosgonimeton
